Biotechnology · South San Francisco, California, United States
$1.13
-0.44% (-$0.00)2026-07-10
Smart-Money SignalNeutral · 46/100— Insider open-market flow is flat over 90 days
Revenue$0
Net Income-$20.0M
EPS$-0.32
Market Cap$69.7M
Price Performance
Historical data including institutional events
Company Profile
B
Bernard Coulie
CEO & Executive Director
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors.
The companyâs lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvÃ8 and αvÃ1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery.
Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
